Microbot Medical (MBOT)

Nasdaq Markedet er åpent

Microbot Medical, Inc. er et medisinteknologiselskap som utvikler robotteknologier for minimalt invasive prosedyrer inne i kroppens rørformede strukturer, et felt som ofte omtales som endoluminal kirurgi. Selskapets arbeid er sentrert rundt ideen om at robotikk kan forbedre kontroll, presisjon og konsistens i kateterbaserte inngrep, samtidig som noe av den fysiske belastningen på leger under prosedyrer reduseres.

Dets ledende plattform er LIBERTY, et endovaskulært robotkirurgisk system utviklet for bruk i en rekke vaskulære intervensjoner. I motsetning til mange kapitalintensive robotplattformer er LIBERTY utformet som et fullstendig engangssystem, noe som er ment å forenkle oppsettet, redusere behovet for store faste installasjoner og håndtere bekymringer knyttet til sterilisering og krysskontaminering. Systemet er bygget for å la leger fjernmanipulere endovaskulære verktøy, noe som potensielt kan bidra til å begrense stråleeksponering fra fluoroskopi og forbedre ergonomien under langvarige prosedyrer.

Microbot Medical opererer som et selskap i utviklingsfasen, med virksomheten fokusert på forskning, design, testing og den regulatoriske prosessen for sine robotenheter. Det rapporterer ett driftssegment: utvikling av robotenheter for endoluminal kirurgi. Den kommersielle muligheten avhenger av klinisk ytelse, regulatoriske godkjenninger, legers adopsjon, sykehusenes innkjøpsbeslutninger og evnen til å demonstrere fordeler sammenlignet med eksisterende manuelle kateterteknikker.

For investorer representerer MBOT en høyt spesialisert eksponering mot medisinsk teknologi. Selskapet er ikke en diversifisert produsent innen helsesektoren; verdien er tett knyttet til fremgangen for LIBERTY og relaterte robotsystemer i det konkurransepregede markedet for minimalt invasive og bildeveiledede prosedyrer.

1.96 USD
−0.01 (-0.51%)

Sist oppdatert

Markedsverdi
132.31M
P/E-tall
P/FCF-tall
P/S-tall
1,260.14
Selskapsverdi
128.66M
Sektor
Health Care
Bransje
Surgical and Medical Instruments and Apparatus
Adresse
25 RECREATION PARK DR SUITE 108, HINGHAM, MA, 02043
GlobeNewswire Inc.

Microbot Medical® Confirms Continued Operational and Commercial Stability Amid Current Geopolitical Event

03. mars 2026, 15:00 P.M.
GlobeNewswire Inc.

Microbot Medical Announces Final Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds

07. okt. 2025, 14:00 P.M.
GlobeNewswire Inc.

Microbot Medical Announces First Closing of Exercise of Outstanding Preferred Investment Options of Up to $92.2 Million in Gross Proceeds

16. sep. 2025, 21:37 P.M.
GlobeNewswire Inc.

Microbot Medical Closes $13 Million Registered Direct Offering

12. feb. 2025, 00:15 A.M.
GlobeNewswire Inc.

Microbot Medical Continues to Ramp Up Patient Enrollment in its Pivotal Human Clinical Trial - GlobeNewswire

09. juli 2024, 14:30 P.M.
Zacks Investment Research

Microbot (MBOT) Inks a New Agreement to Begin Trial on LIBERTY - Zacks Investment Research

04. juli 2024, 20:00 P.M.
GlobeNewswire Inc.

Microbot Medical Partners with Brigham and Women's Hospital for Its Pivotal Human Clinical Trial

20. juni 2024, 14:25 P.M.
GlobeNewswire Inc.

Microbot Medical Announces Brigham and Women's Hospital as a Site for its Pivotal Human Clinical Trial

17. juni 2024, 14:30 P.M.
GlobeNewswire Inc.

Microbot Medical Announces Closing of $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

04. juni 2024, 22:20 P.M.
PennyStocks

Should Risk Averse Traders Buy Penny Stocks?

04. juni 2024, 12:20 P.M.
GlobeNewswire Inc.

Microbot Medical Announces $2.35 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

03. juni 2024, 18:11 P.M.
GlobeNewswire Inc.

Microbot Medical Has Received FDA Approval to Proceed with its Pivotal Human Clinical Trial

03. juni 2024, 14:20 P.M.
GlobeNewswire Inc.

Microbot Medical Announces Positive Results from the First Phase of its Collaboration with Corewell Health™

29. apr. 2024, 14:30 P.M.
GlobeNewswire Inc.

Microbot Medical Shares Status Following Recent Geopolitical Events

15. apr. 2024, 14:30 P.M.
Zacks Investment Research

Microbot Medical (MBOT) Files IDE to Start Human Clinical Study

07. feb. 2024, 16:08 P.M.
GlobeNewswire Inc.

Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US

05. feb. 2024, 13:30 P.M.
GlobeNewswire Inc.

Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving all Associated Legal Matters

30. jan. 2024, 13:20 P.M.
GlobeNewswire Inc.

Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study

18. jan. 2024, 13:20 P.M.
Zacks Investment Research

Microbot Medical (MBOT) Announces Positive GLP Study Results

03. jan. 2024, 16:12 P.M.
GlobeNewswire Inc.

Microbot Medical Announces Exercise of Outstanding Preferred Investment Options for $2.73 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules

29. des. 2023, 14:00 P.M.
Markedsverdi
132.31M
Selskapsverdi
128.66M
P/E-tall
P/B-tall
1.79
P/S-tall
1,260.14
EV / EBITDA-forhold
-8.04
EV / omsetning
1,225.31
Resultat per aksje
-0.21
Utbytterente
0%
P/FCF-tall
P/CF-tall
Fri kontantstrøm
-15.38M
Avkastning på egenkapital
-19.18%
Avkastning på eiendeler
-18.21%
Gjeld / egenkapital
0
Likviditetsgrad I
22.54
Likviditetsgrad II
21.87
Kontanter
1.08
Snittvolum
1.78M
Fundamentalpris (snapshot)
1.97

Resultatregnskap

Post 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Omsetning 105K
Bruttofortjeneste 2K
Driftsresultat -4.32M -4.14M -3.86M -3.72M -3.02M
Driftsresultat før avskrivninger (EBITDA) -4.31M -4.13M -3.85M -3.71M -3.01M
Nettoresultat -3.67M -3.46M -3.58M -3.5M -2.6M
Grunnleggende EPS -0.05 -0.04 -0.07 -0.1 -0.08
Utvanet EPS -0.05 -0.04 -0.07 -0.1 -0.08

Balanse

Post 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Sum eiendeler 78.07M 81.54M 81.76M 33.13M 30.89M
Sum gjeld 3.96M 3.99M 3.54M 2.77M 1.94M
Egenkapital 74.11M 77.55M 78.22M 30.36M 28.95M
Kontanter og ekvivalenter 3.66M 3.91M 6.7M 4.08M 3.22M
Omløpsmidler 76.33M 79.82M 80.73M 32.84M 30.61M
Kortsiktig gjeld 3.39M 3.42M 2.93M 2.73M 1.89M

Kontantstrøm

Post 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1
Kontantstrøm fra drift -5.05M -3.76M -3.84M -2.57M -2.87M
Kontantstrøm fra investeringer 5M -1.53M -44.71M -1.31M -24.83M
Kontantstrøm fra finansiering 2.51M 51.18M 4.75M 27.81M
Endring i kontanter -56K -2.79M 2.62M 870K 102K
Type Rapport Dato Lenke
edgar index 8-K — Microbot Medical Inc. Vis rapport
eight k text 8-K — 8-K Vis rapport
edgar index 8-K — Microbot Medical Inc. Vis rapport
eight k text 8-K — 8-K Vis rapport
edgar index 8-K — Microbot Medical Inc. Vis rapport
eight k text 8-K — 8-K Vis rapport
edgar index 8-K — Microbot Medical Inc. Vis rapport
eight k text 8-K — 8-K Vis rapport
edgar index 10-Q — Microbot Medical Inc. Vis rapport
edgar index 8-K — Microbot Medical Inc. Vis rapport
eight k text 8-K — 8-K Vis rapport
edgar index 8-K — Microbot Medical Inc. Vis rapport
eight k text 8-K — 8-K Vis rapport
edgar index 8-K — Microbot Medical Inc. Vis rapport
eight k text 8-K — 8-K Vis rapport
edgar index 8-K — Microbot Medical Inc. Vis rapport
eight k text 8-K — 8-K Vis rapport
edgar index 8-K — Microbot Medical Inc. Vis rapport
edgar index 424B5 — Microbot Medical Inc. Vis rapport
eight k text 8-K — 8-K Vis rapport
edgar index 4 — Microbot Medical Inc. Vis rapport
edgar index 4 — Microbot Medical Inc. Vis rapport
edgar index 4 — Microbot Medical Inc. Vis rapport
edgar index 4 — Microbot Medical Inc. Vis rapport
edgar index 4 — Microbot Medical Inc. Vis rapport
edgar index 4 — Microbot Medical Inc. Vis rapport
form 4 Form 4 — Wilson David James Vis rapport
form 4 Form 4 — Wenderow Tal Baruch Vis rapport
form 4 Form 4 — Madden Martin J. Vis rapport
form 4 Form 4 — Stockburger Aileen Ptucha Vis rapport
form 4 Form 4 — Laxminarain Prattipati Vis rapport
form 4 Form 4 — Burell Scott R Vis rapport
edgar index 8-K — Microbot Medical Inc. Vis rapport
edgar index 10-K — Microbot Medical Inc. Vis rapport
eight k text 8-K — 8-K Vis rapport
ten k section 10-K — business Vis rapport
ten k section 10-K — mda Vis rapport
ten k section 10-K — risk_factors Vis rapport
edgar index 8-K — Microbot Medical Inc. Vis rapport
edgar index 8-K — Microbot Medical Inc. Vis rapport
edgar index 8-K — Microbot Medical Inc. Vis rapport
edgar index 8-K — Microbot Medical Inc. Vis rapport
edgar index 8-K — Microbot Medical Inc. Vis rapport
edgar index 8-K — Microbot Medical Inc. Vis rapport
edgar index 8-K — Microbot Medical Inc. Vis rapport
edgar index 4 — Microbot Medical Inc. Vis rapport
edgar index 4 — Microbot Medical Inc. Vis rapport
edgar index 4 — Microbot Medical Inc. Vis rapport
edgar index 4 — Microbot Medical Inc. Vis rapport
edgar index 8-K — Microbot Medical Inc. Vis rapport
form 4 Form 4 — Sharon Simon Vis rapport
form 4 Form 4 — Vaknin Rachel Vis rapport
form 4 Form 4 — Gadot Harel Vis rapport
form 4 Form 4 — Diaz-Cartelle Juan Vis rapport
edgar index 8-K — Microbot Medical Inc. Vis rapport
edgar index 8-K — Microbot Medical Inc. Vis rapport
edgar index SCHEDULE 13G — Microbot Medical Inc. Vis rapport
edgar index 8-K — Microbot Medical Inc. Vis rapport
edgar index 8-K — Microbot Medical Inc. Vis rapport
edgar index 424B3 — Microbot Medical Inc. Vis rapport
edgar index 424B3 — Microbot Medical Inc. Vis rapport
edgar index 10-Q — Microbot Medical Inc. Vis rapport
edgar index SCHEDULE 13G/A — Microbot Medical Inc. Vis rapport
edgar index 8-K — Microbot Medical Inc. Vis rapport
edgar index SCHEDULE 13G/A — Microbot Medical Inc. Vis rapport
edgar index S-3/A — Microbot Medical Inc. Vis rapport
edgar index S-3/A — Microbot Medical Inc. Vis rapport
edgar index 8-K — Microbot Medical Inc. Vis rapport
edgar index S-3 — Microbot Medical Inc. Vis rapport
edgar index S-3 — Microbot Medical Inc. Vis rapport
edgar index 8-K — Microbot Medical Inc. Vis rapport
edgar index 8-K — Microbot Medical Inc. Vis rapport
edgar index 8-K — Microbot Medical Inc. Vis rapport
edgar index 8-K — Microbot Medical Inc. Vis rapport
edgar index D — Microbot Medical Inc. Vis rapport